NewEdge Advisors’s Marker Therapeutics MRKR Stock Holding History

NewEdge Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-149,000	Closed	-$222K	–	4292
2025 Q4	$222K	Buy	+149,000	New	+$169K	﹤0.01%	2522

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

NewEdge Advisors's MRKR Position: Q1 2026 in Review

NewEdge Advisors sold out of Marker Therapeutics (MRKR) in Q1 2026, closing a stake of 149,000 shares — an estimated $222K sold.

NewEdge Advisors first reported a position in MRKR in Q4 2025 and held it in 1 quarter. The position peaked at $222K in Q4 2025. 35 funds tracked by Wall St. Rank hold MRKR as of Q1 2026.

NewEdge Advisors reported no remaining Marker Therapeutics position as of Q1 2026 after selling out during the quarter.
NewEdge Advisors sold 149,000 Marker Therapeutics shares in Q1 2026, an estimated $222K.
NewEdge Advisors first reported a position in Marker Therapeutics in Q4 2025 and held it in 1 quarter.
NewEdge Advisors's Marker Therapeutics position peaked at $222K in Q4 2025.
35 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.